Literature DB >> 11339919

Population-based study of microinvasive adenocarcinoma of the uterine cervix.

J C Webb1, C R Key, C R Qualls, H O Smith.   

Abstract

OBJECTIVE: To analyze lymph node status and survival rates of women with microinvasive cervical adenocarcinoma (International Federation of Gynecology and Obstetrics stages IA(1) and IA(2)).
METHODS: The Surveillance, Epidemiology, and End Results (SEER) Public-Use Database was used to identify cases of microinvasive cervical adenocarcinoma diagnosed between 1988 and 1997. Variables analyzed included stage, extent of surgery, lymph node status, radiation therapy, and age. Statistics included analysis of trends, analysis of variance, log-rank test, one-sided binomial confidence interval estimation, and power analysis.
RESULTS: Among 301 reported cases, 131 had stage IA(1) and 170 IA(2) disease. Simple hysterectomies were done in 54 women with IA(1) and 64 with IA(2) disease and radical hysterectomies were done in 50 and 83 women, respectively. Only one of 140 women who had lymphadenectomy had a single positive lymph node. There were four tumor-related deaths (one with IA(1), and three with IA(2) disease). There were no deaths among 96 women (47, IA(1); 49, IA(2)) treated by simple hysterectomy alone. The mean follow-up was 46.5 months (range 1--119). The censored survival rate was 98.7% overall (99.2% IA(1), 98.2% IA(2)). Power analysis estimated that 720 patients would be required in each group to detect a 2% difference in survival. Using one-sided 95% confidence interval estimations, the risk-adverse events rate for IA(1) was no more than 3.57%, and 4.50% for IA(2) disease.
CONCLUSION: Prognosis is excellent for microinvasive adenocarcinoma of the uterine cervix. In 96 cases (31.9%), simple hysterectomy alone proved adequate.

Entities:  

Mesh:

Year:  2001        PMID: 11339919     DOI: 10.1016/s0029-7844(01)01330-8

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  6 in total

1.  New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome.

Authors:  Andres A Roma; Toni-Ann Mistretta; Andrea Diaz De Vivar; Kay J Park; Isabel Alvarado-Cabrero; Golnar Rasty; Jose G Chanona-Vilchis; Yoshiki Mikami; Sung R Hong; Norihiro Teramoto; Rouba Ali-Fehmi; Denise Barbuto; Joanne K L Rutgers; Elvio G Silva
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

2.  Pattern-based classification of invasive endocervical adenocarcinoma, depth of invasion measurement and distinction from adenocarcinoma in situ: interobserver variation among gynecologic pathologists.

Authors:  Carlos Parra-Herran; Monica Taljaard; Bojana Djordjevic; M Carolina Reyes; Lauren Schwartz; John K Schoolmeester; Ricardo R Lastra; Charles M Quick; Anna Laury; Golnar Rasty; Marisa R Nucci; Brooke E Howitt
Journal:  Mod Pathol       Date:  2016-05-13       Impact factor: 7.842

3.  Clinical Epidemiology of Microinvasive Cervical Carcinoma in an Italian Population Targeted by a Screening Programme.

Authors:  Lauro Bucchi; Silvano Costa; Silvia Mancini; Flavia Baldacchini; Orietta Giuliani; Alessandra Ravaioli; Rosa Vattiato; Federica Zamagni; Paolo Giorgi Rossi; Cinzia Campari; Debora Canuti; Priscilla Sassoli de Bianchi; Stefano Ferretti; Fabio Falcini
Journal:  Cancers (Basel)       Date:  2022-04-22       Impact factor: 6.575

Review 4.  Adenocarcinoma of the cervix.

Authors:  John O Schorge; Lynne M Knowles; Jayanthi S Lea
Journal:  Curr Treat Options Oncol       Date:  2004-04

5.  Tumor volume and lymphovascular space invasion as a prognostic factor in early invasive adenocarcinoma of the cervix.

Authors:  Isao Murakami; Takuma Fujii; Kaori Kameyama; Takashi Iwata; Miyuki Saito; Kaneyuki Kubushiro; Daisuke Aoki
Journal:  J Gynecol Oncol       Date:  2012-07-02       Impact factor: 4.401

6.  Cancer of the cervix uteri: 2021 update.

Authors:  Neerja Bhatla; Daisuke Aoki; Daya Nand Sharma; Rengaswamy Sankaranarayanan
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.